Ascentage Pharma Group International (AAPG) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -779.66M | -452.56M | 217.31M | -390.29M | -361.07M | -441.86M | -335.8M | -366.66M | -216.49M | -361.86M | -311.34M | -301.21M |
| Operating CF Margin % | -233.34% | -193.65% | 138.5% | -47.38% | -455.42% | -309.64% | -320.25% | -349.68% | -1448.56% | -2791.05% | -5001.41% | -4838.69% |
| Operating CF Growth % | -458.78% | -15.96% | 160.18% | 11.67% | -7.53% | -20.51% | -55.12% | -1.33% | 30.47% | -20.14% | -41.05% | -35.77% |
| Net Income | -639.96M | -1.18B | -568.43M | 163M | -523.29M | -409.58M | -443.59M | -420.52M | -416.12M | -416.12M | -337.72M | -320.27M |
| Depreciation & Amortization | 41.9M | 6.04M | 45.86M | 47.31M | 47.62M | 45.58M | 4.56M | 31.04M | 2.2M | 14.52M | 13.19M | 13.73M |
| Stock-Based Compensation | 0 | 26.1M | 12.19M | 8.73M | 13.25M | 18.25M | 16.53M | 11.05M | 20.03M | 23.49M | 37.01M | 33.42M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -181.6M | 702.88M | 640.33M | -609.33M | 170.35M | -155.97M | 34.48M | -40.45M | 82.59M | -78.57M | 31.44M | -4.22M |
| Working Capital Changes | 0 | 0 | 87.36M | 0 | -69.01M | 59.87M | 52.21M | 52.21M | 94.83M | 94.83M | -55.25M | -23.87M |
| Change in Receivables | 0 | 0 | 62.75M | 0 | -91.54M | -1K | -194K | -194K | -26.98M | -26.98M | 0 | 0 |
| Change in Inventory | 0 | 0 | 9.57M | 0 | -6.72M | -1K | -2.76M | -2.76M | -1.97M | -1.97M | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | -23.11M | 12.35M | 12.35M | 0 | 0 | 0 | 0 |
| Cash from Investing | -302.52M | -695.7M | -235.32M | -132.21M | 87.21M | -56.93M | -226.76M | -147.43M | 526.79M | -1B | 88.57M | -207.66M |
| Capital Expenditures | -7.75M | -19.79M | -7.76M | -16.53M | -12.13M | -33.98M | -101.64M | -101.64M | -217.71M | -217.71M | -124.96M | -124.96M |
| CapEx % of Revenue | 2.32% | 8.47% | 4.95% | 2.01% | 15.3% | 23.81% | 96.94% | 96.94% | 1456.72% | 1679.19% | 2007.4% | 2007.4% |
| Acquisitions | -765.44K | -42.8M | -9.52M | 0 | -20M | 1.49M | -10M | -10M | -18.1M | -18.1M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -14 | -8 | -218.04M | -116.78K | -7.97M | 8.39M | -50.11M | 29.21M | 759.61M | -771.22M | 141.48M | -154.75M |
| Cash from Financing | 1.6B | 964.7M | -53.39M | 433.1M | -69.53M | 522.2M | 162.83M | 483.03M | 712.25M | 1.08B | 826.73M | 195.61M |
| Debt Issued (Net) | 262.63M | 49.68M | -44.47M | -98.85M | 115.82M | -13.36M | 347.94M | 347.94M | 274.29M | 274.29M | 216.4M | 216.4M |
| Equity Issued (Net) | 1.35B | 929.21M | 4.8M | -1.96M | -5.92M | 470.08M | -13.39M | -13.39M | 637.39M | 637.39M | 317.11M | 317.11M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 1.39K | -9.2M | 1.98M | -1.96M | -5.92M | -1K | -13.39M | -13.39M | -12.94M | -12.94M | 0 | 0 |
| Other Financing | -7.2M | -14.19M | -13.72M | 533.91M | -179.43M | 65.47M | -171.72M | 148.48M | -199.43M | 172.7M | 293.21M | -337.9M |
| Net Change in Cash | -419.13M | 760.37M | -187.6M | 11.68M | -481.05M | 157.69M | -361.25M | -361.25M | 655.08M | 686.91M | 624.9M | -464.46M |
| Free Cash Flow | -787.41M | -452.16M | 235.27M | -370.92M | -369.75M | -413.18M | -445.44M | -445.44M | -520.65M | -520.65M | -430.72M | -430.72M |
| FCF Margin % | -235.66% | -193.48% | 149.95% | -45.03% | -466.36% | -289.54% | -424.81% | -424.81% | -3483.8% | -4015.84% | -6919.13% | -6919.13% |
| FCF Growth % | -434.68% | -21.9% | 163.63% | 10.23% | 16.99% | 7.24% | 14.45% | 14.45% | -20.88% | -20.88% | -59.02% | -59.02% |
| FCF per Share | -8.50 | -5.29 | 3.01 | -5.01 | -5.10 | -23.42 | -27.03 | -27.03 | -32.72 | -32.72 | -31.92 | -31.92 |
| FCF Conversion (FCF/Net Income) | 1.22x | 0.77x | -0.38x | -2.39x | 0.69x | 1.10x | 0.76x | 0.83x | 0.55x | 0.92x | 0.92x | 0.89x |
| Interest Paid | 0 | 0 | 27.4M | 33.16M | 37.97M | 54.38M | 24.92M | 24.92M | 8.4M | 8.4M | 2.97M | 2.97M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |